Sunesis Pharmaceuticals (SNSS) Tops Q3 EPS by 6c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q3 EPS of ($0.09), $0.06 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $1.09 million.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Goldman Sachs Downgrades Carl Zeiss Meditec AG (AFX:GR) (CZMWY) to Sell
• Raymond James Reiterates Outperform Rating on Walt Disney (DIS)